Conclusion: Low levels of ER and PgR are predictive of the benefit of adding chemotherapy to endocrine therapy. Low PgR may add further prediction among pre- ...
Low levels of ER and PgR are predictive of the benefit of adding chemotherapy to endocrine therapy. Low PgR may add further prediction.
5. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and ...
Nov 8, 2012 · Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer : predictive value of centrally reviewed expression of ...
Chemo-endocrine therapy yielded DFS superior to endocrine therapy alone for patients with receptor-absent tumors, and in some cases also for those with low ...
During a median follow-up of 5.2 years, patients who received ET improved BCSS. Of them, those with AI/T + AI had increased BCSS compared to patients without ET ...
People also ask
What are predictive markers of endocrine response in breast cancer?
Is adherence to adjuvant endocrine therapy a factor for ethnic differences in breast cancer outcomes in New Zealand?
What is the benefit of adjuvant chemotherapy in breast cancer?
Is adjuvant better than neoadjuvant triple negative breast cancer?
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
... International Breast Cancer Study Group trials of adjuvant chemoendocrine therapy vs endocrine therapy alone for node-negative breast cancer. A high Ki-67 ...
Jul 7, 2020 · In this study, 37.2% of patients with low ER expression received endocrine therapy, and there was no statistically significant difference ...
Jul 20, 2020 · This study reveals that in appropriately selected patients, NET can provide equivalent clinical benefit to neoadjuvant chemotherapy in the same cohort.